| Janine B Peterson-hale, MD | |
|
2901 Brooks St, Missoula, MT 59801-7703 | |
| (406) 721-0918 | |
| Not Available |
| Full Name | Janine B Peterson-hale |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 30 Years |
| Location | 2901 Brooks St, Missoula, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376638585 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 8228 (Montana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Montana Clinic Pc | 2466365002 | 40 |
News Archive
New research by a University of Georgia scientist reveals that girls who are maltreated show higher levels of inflammation at an early age than boys who are maltreated or children who have not experienced abuse. This finding may forecast chronic mental and physical health problems in midlife.
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.
A survey of nurses anaesthetists in Sweden identified difficulties in preparing children for surgery but also found that when the hospital and the staff were flexible in their approaches, the children's anxiety could be reduced. These approaches included varying the operation schedule, provided it do not create risk to the child, and pre-surgical visits with operating staff.
Gilead Sciences, Inc. announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA).
› Verified 8 days ago
| Entity Name | Western Montana Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942253182 PECOS PAC ID: 2466365002 Enrollment ID: O20031110000361 |
News Archive
New research by a University of Georgia scientist reveals that girls who are maltreated show higher levels of inflammation at an early age than boys who are maltreated or children who have not experienced abuse. This finding may forecast chronic mental and physical health problems in midlife.
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.
A survey of nurses anaesthetists in Sweden identified difficulties in preparing children for surgery but also found that when the hospital and the staff were flexible in their approaches, the children's anxiety could be reduced. These approaches included varying the operation schedule, provided it do not create risk to the child, and pre-surgical visits with operating staff.
Gilead Sciences, Inc. announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA).
› Verified 8 days ago
| Entity Name | Clark Fork Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538384987 PECOS PAC ID: 1850491960 Enrollment ID: O20070702000592 |
News Archive
New research by a University of Georgia scientist reveals that girls who are maltreated show higher levels of inflammation at an early age than boys who are maltreated or children who have not experienced abuse. This finding may forecast chronic mental and physical health problems in midlife.
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.
A survey of nurses anaesthetists in Sweden identified difficulties in preparing children for surgery but also found that when the hospital and the staff were flexible in their approaches, the children's anxiety could be reduced. These approaches included varying the operation schedule, provided it do not create risk to the child, and pre-surgical visits with operating staff.
Gilead Sciences, Inc. announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janine B Peterson-hale, MD Po Box 7609, Missoula, MT 59807-7609 Ph: (406) 721-5600 | Janine B Peterson-hale, MD 2901 Brooks St, Missoula, MT 59801-7703 Ph: (406) 721-0918 |
News Archive
New research by a University of Georgia scientist reveals that girls who are maltreated show higher levels of inflammation at an early age than boys who are maltreated or children who have not experienced abuse. This finding may forecast chronic mental and physical health problems in midlife.
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.
A survey of nurses anaesthetists in Sweden identified difficulties in preparing children for surgery but also found that when the hospital and the staff were flexible in their approaches, the children's anxiety could be reduced. These approaches included varying the operation schedule, provided it do not create risk to the child, and pre-surgical visits with operating staff.
Gilead Sciences, Inc. announced today that its Marketing Authorisation Application (MAA) for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the European Medicines Agency (EMA).
› Verified 8 days ago
Diana Griffith, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2827 Fort Missoula Rd, Missoula, MT 59804 Phone: 406-728-4100 | |
Dr. Amanda A Morey, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-329-5635 | |
Dr. Kevin Granger Eichhorn, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Saint Patrick Hospital Emergency Department, 500 West Broadway, Missoula, MT 59801 Phone: 406-329-5635 | |
Elizabeth J Grimley, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-721-5600 Fax: 406-721-3907 | |
David Westphal, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2827 Fort Missoula Rd, Missoula, MT 59804 Phone: 406-721-4800 | |
Dr. Douglas Carl Melzer, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 303-720-9622 | |
Dr. Robert C Mcdevitt, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-721-5600 Fax: 406-721-3907 |